News - OBI Pharma 台灣浩鼎

2024.Mar.12

Corporate

OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London

2024.Mar.11

Corporate

OBI announces the termination of OBI-3424 Phase II trial

2024.Jan.03

Corporate

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

2023.Dec.29

未分類

Corporate

Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.

2023.Dec.06

未分類

Corporate

OBI Pharma proprietary ADC technology platform “plug and play”

2023.Nov.23

未分類

Corporate

Award & Certification

OBI Achieves ISO/IEC 27001 International Information Security Certification

2023.Nov.01

未分類

Sustainability

OBI VOLUNTEERS ON A MISSION!

2023.Jun.02

Corporate

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. appointed as Chief Executive Officer

2023.Apr.20

Corporate

Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

2023.Apr.10

Corporate

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Announcements

Latest announcements

Events

Latest events